TABLE 2.
Clinical and demographic data in patients receiving empagliflozin therapy in Group 2
| Compared parameters | Baseline treatment | Group 2 | p |
|---|---|---|---|
| Mean age, years (SD) | 52.5±7.5 | ||
| Sex male/female, (%) | 13 (%59)/9 (41) | ||
| Duration of diabetes, years (SD) | 14.6±6.8 | ||
| HbA1c, % (SD) | 9.6±1.7 | 8.4±1.4 | 0.001 |
| FPG, mg/dl (SD) | 217.1±75.5 | 180.3±50.4 | 0.006 |
| Creatinin, mg/dl (SD) | 0.76±0.10 | 0.80±0.11 | 0.088 |
| eGFR, mL/minper 1.73 m2 (SD) | 102.4±16.2 | 97.3±20.5 | 0.185 |
| Total cholesterol, mg/dL (SD) | 211.9±60.5 | 202.2±58.3 | 0.067 |
| LDL-cholesterol, mg/dL (SD) | 127.3±44.1 | 115.3±39.9 | 0.071 |
| HDL-cholesterol, mg/dL (SD) | 41.6±10.9 | 45.9±11.7 | 0.724 |
| Triglyceride, mg/dL (SD) | 208.9±140.9 | 206.1±145.8 | 0.820 |
| Weight, kg (SD) | 82.8±13.1 | 79.0±12.4 | 0.000 |
| SBP, mmHg (SD) | 137.2±8.6 | 127.6±5.0 | 0.000 |
| DBP, mmHg (SD) | 86.3±7.7 | 79.6±6.0 | 0.000 |
| Urinary tract infection (%) | 1 (%3.5) | 2 (%7.1) | 0.778 |
| Genital infection (%) | 1 (%3.5) | 2 (%7.1) | 0.778 |
Baseline treatment: Metformin (2000 mg/day) plus glyclazide (60 mg/day); SD: Standard deviation; FPG: Fasting plasma glucose; eGFR: Estimated glomerular filtration rate [using the Modification of Diet in Renal Disease (MDRD) equation]; SBP: Systolic blood pressure; DBP: Diastolic blood pressure.